Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure

THE WOODLANDS, Texas, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies can support a new drug application (NDA) submission for an indication to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure.

Excerpt from:
Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure

Read more
PDS Biotech Releases White Paper Detailing the Potential of the Versamune® Platform in Overcoming a Major Limitation of Immuno-Oncology

Promotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment Promotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment

See the original post here:
PDS Biotech Releases White Paper Detailing the Potential of the Versamune® Platform in Overcoming a Major Limitation of Immuno-Oncology

Read more
Grey Cloak Tech Fuel4Thought™ Migraine Formula Results Published in World Journal of Advanced Research and Reviews

Fuel4Thought™ proprietary formulation pilot study reduced the number of Migraine episodes by 39% and the average duration by 61% Fuel4Thought™ proprietary formulation pilot study reduced the number of Migraine episodes by 39% and the average duration by 61%

Follow this link:
Grey Cloak Tech Fuel4Thought™ Migraine Formula Results Published in World Journal of Advanced Research and Reviews

Read more
Global Adoption of Biologicals Accelerates as Marrone Bio’s Grandevo® WDG Bioinsecticide is Approved for Use in New Zealand, Chile and on Hemp in…

DAVIS, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations (NASDAQ: MBII) (MBI), a global provider of bio-based crop protection and plant health products, today announced that it recently received approval for Grandevo WDG Bioinsecticide for use in New Zealand and Chile. Grandevo WDG and Grandevo CG have also been approved for use on hemp by the U.S. Environmental Protection Agency (EPA).

Read the original here:
Global Adoption of Biologicals Accelerates as Marrone Bio’s Grandevo® WDG Bioinsecticide is Approved for Use in New Zealand, Chile and on Hemp in...

Read more
RoosterBio Partners with Sartorius to Advance Cell and Gene Therapy Manufacturing

RoosterBio’s innovative hMSCs and bioprocess media systems, coupled with Sartorius’s scalable closed system bioreactor, downstream processing, and analytics, offers end-to-end hMSC manufacturing solutions for the field of regenerative medicine. RoosterBio’s innovative hMSCs and bioprocess media systems, coupled with Sartorius’s scalable closed system bioreactor, downstream processing, and analytics, offers end-to-end hMSC manufacturing solutions for the field of regenerative medicine.

Read the original post:
RoosterBio Partners with Sartorius to Advance Cell and Gene Therapy Manufacturing

Read more
Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference

MONTREAL, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer and Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer will present at the B. Riley Virtual Oncology Investor Conference on Wednesday, January 20, 2021 at 3:30 p.m. ET.

Read this article:
Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference

Read more